LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Lexicon Pharmaceuticals Inc

Closed

SectorHealthcare

0.82 -10.87

Overview

Share price change

24h

Current

Min

0.82

Max

0.93

Key metrics

By Trading Economics

Income

8.5M

-25M

Sales

-25M

1.3M

EPS

-0.07

Profit margin

-2,004.358

Employees

103

EBITDA

4.1M

-26M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+307.78% upside

Dividends

By Dow Jones

Next Earnings

31 lip 2025

Market Stats

By TradingEconomics

Market Cap

22M

267M

Previous open

11.69

Previous close

0.82

News Sentiment

By Acuity

17%

83%

27 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Lexicon Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 lis 2024, 12:42 UTC

Major Market Movers

Lexicon Pharma Shares Slide Premarket After Negative FDA Panel Vote

Peer Comparison

Price change

Lexicon Pharmaceuticals Inc Forecast

Price Target

By TipRanks

307.78% upside

12 Months Forecast

Average 3.67 USD  307.78%

High 6 USD

Low 1 USD

Based on 3 Wall Street analysts offering 12 month price targets forLexicon Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

0.6863 / 0.72Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Very Strong Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

27 / 380 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.